P1800000
Pindolol
European Pharmacopoeia (EP) Reference Standard
别名:
1-(1H-Indol-4-yloxy)-3-(isopropylamino)-2-propanol, 1-(1H-Indol-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H20N2O2
化学文摘社编号:
分子量:
248.32
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
pindolol
制造商/商品名称
EDQM
mp
167-171 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
CC(C)NCC(O)COc1cccc2[nH]ccc12
InChI
1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3
InChI key
JZQKKSLKJUAGIC-UHFFFAOYSA-N
基因信息
human ... ADRB1(153), ADRB2(154)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Pindolol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
β1-adrenoceptor antagonist; putative 5-HT1A serotonin receptor agonist; vasodilator.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
涉药品监管产品
此项目有
Francesc Artigas et al.
Current drug targets, 7(2), 139-147 (2006-02-16)
Pindolol, a partial beta-adrenoceptor/5-HT1A receptor antagonist was first used to accelerate the onset of action of antidepressant drugs in 1994. Since then, it has been used in more than a dozen controlled trials to examine whether it can reduce the
Rebecca Segrave et al.
Human psychopharmacology, 20(3), 163-174 (2005-01-14)
Co-administration of pindolol with SSRIs in patients with depression has been suggested as a way to both hasten and augment antidepressant response. Clinical trials have examined the efficacy of this treatment regime and conflicting results have been reported. The present
G G Kinney et al.
Molecular neurobiology, 21(3), 137-152 (2001-05-31)
The development of selective serotonin reuptake inhibitors (SSRIs) provided a major advancement in the treatment of depression. However, these drugs suffer from a variety of drawbacks, most notably a delay in the onset of efficacy. One hypothesis suggests that this
A Fanchamps
American heart journal, 104(2 Pt 2), 388-406 (1982-08-01)
The antihypertensive effect of pindolol has been demonstrated in several hundred clinical trials performed in many countries. The results of several representative trials will be reviewed in this article. In a cooperative study of pindolol by Swiss internists, blood pressure
D Martinez et al.
Biological psychiatry, 48(8), 844-853 (2000-11-07)
Preclinical studies suggest that augmentation of selective serotonin (5-HT) reuptake inhibitors by the 5-HT(1A) receptor agent pindolol might reduce the delay between initiation of treatment and antidepressant response, an effect largely mediated by blockade of 5-HT(1A) autoreceptors in the dorsal
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持